BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ben-Amor AF, Trochanov A, Fischer TZ. Cumulative Review of Thrombotic Microangiopathy, Thrombotic Thrombocytopenic Purpura, and Hemolytic Uremic Syndrome Reports with Subcutaneous Interferon β-1a. Adv Ther 2015;32:445-54. [PMID: 25991578 DOI: 10.1007/s12325-015-0212-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Jia H, Thelwell C, Dilger P, Bird C, Daniels S, Wadhwa M. Endothelial cell functions impaired by interferon in vitro: Insights into the molecular mechanism of thrombotic microangiopathy associated with interferon therapy. Thromb Res. 2018;163:105-116. [PMID: 29407621 DOI: 10.1016/j.thromres.2018.01.039] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
2 Ayrignac X, Bilodeau P, Prat A, Girard M, Labauge P, Le Lorier J, Larochelle C, Duquette P. Assessing the risk of multiple sclerosis disease-modifying therapies. Expert Review of Neurotherapeutics 2019;19:695-706. [DOI: 10.1080/14737175.2019.1627201] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Kavanagh D, McGlasson S, Jury A, Williams J, Scolding N, Bellamy C, Gunther C, Ritchie D, Gale DP, Kanwar YS, Challis R, Buist H, Overell J, Weller B, Flossmann O, Blunden M, Meyer EP, Krucker T, Evans SJ, Campbell IL, Jackson AP, Chandran S, Hunt DP. Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature. Blood. 2016;128:2824-2833. [PMID: 27663672 DOI: 10.1182/blood-2016-05-715987] [Cited by in Crossref: 55] [Cited by in F6Publishing: 44] [Article Influence: 9.2] [Reference Citation Analysis]
4 Lamanna WC, Holzmann J, Cohen HP, Guo X, Schweigler M, Stangler T, Seidl A, Schiestl M. Maintaining consistent quality and clinical performance of biopharmaceuticals. Expert Opinion on Biological Therapy 2018;18:369-79. [DOI: 10.1080/14712598.2018.1421169] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 6.5] [Reference Citation Analysis]
5 Sánchez-soblechero A, Cuello J, Martínez Ginés M, Lozano Ros A, Romero Delgado F, De Andrés C, Goicochea Briceño H, García Domínguez J. Recurrent intracranial hemorrhage in a patient with relapsing multiple sclerosis under interferon-β therapy. Neurología (English Edition) 2022;37:77-9. [DOI: 10.1016/j.nrleng.2021.02.007] [Reference Citation Analysis]
6 Iacopo G, Allinovi M, Caroti L, Cirami LC. Broad spectrum of interferon-related nephropathies—glomerulonephritis, systemic lupus erythematosus-like syndrome and thrombotic microangiopathy: A case report and review of literature. WJN 2019;8:109-17. [DOI: 10.5527/wjgo.v8.i7.109] [Reference Citation Analysis]
7 Gianassi I, Allinovi M, Caroti L, Cirami LC. Broad spectrum of interferon-related nephropathies-glomerulonephritis, systemic lupus erythematosus-like syndrome and thrombotic microangiopathy: A case report and review of literature. World J Nephrol 2019; 8(7): 109-117 [PMID: 31750091 DOI: 10.5527/wjn.v8.i7.109] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Soleimani B, Murray K, Hunt D. Established and Emerging Immunological Complications of Biological Therapeutics in Multiple Sclerosis. Drug Saf 2019;42:941-56. [PMID: 30830572 DOI: 10.1007/s40264-019-00799-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
9 Doskas T, Dardiotis E, Vavougios GD, Ntoskas KT, Sionidou P, Vadikolias K. Stroke risk in multiple sclerosis: a critical appraisal of the literature. International Journal of Neuroscience. [DOI: 10.1080/00207454.2022.2056459] [Reference Citation Analysis]
10 Klotz L, Havla J, Schwab N, Hohlfeld R, Barnett M, Reddel S, Wiendl H. Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. Ther Adv Neurol Disord 2019;12:1756286419836571. [PMID: 30967901 DOI: 10.1177/1756286419836571] [Cited by in Crossref: 41] [Cited by in F6Publishing: 35] [Article Influence: 13.7] [Reference Citation Analysis]
11 Lodi L, Mastrolia MV, Bello F, Rossi GM, Angelotti ML, Crow YJ, Romagnani P, Vaglio A. Type I interferon-related kidney disorders. Kidney Int 2022:S0085-2538(22)00213-7. [PMID: 35339535 DOI: 10.1016/j.kint.2022.02.031] [Reference Citation Analysis]